Versant Capital Management’s PTC Therapeutics PTCT Stock Holding History

Versant Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.28K	Hold	28	–	–	﹤0.01%	2546
2026 Q1	$1.91K	Buy	28 +12	+75%	+$850	﹤0.01%	2575
2025 Q4	$1.22K	Hold	16	–	–	﹤0.01%	2510
2025 Q3	$982	Hold	16	–	–	﹤0.01%	2512
2025 Q2	$781	Buy	+16	New	+$760	﹤0.01%	2515
2023 Q3	–	Sell	-14	Closed	-$569	–	2030
2023 Q2	$569	Buy	+14	New	+$685	﹤0.01%	1805
2021 Q3	–	Sell	-17	Closed	-$1K	–	1562
2021 Q2	$1K	Buy	+17	New	+$728	﹤0.01%	1345

Other funds holding PTCT

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Versant Capital Management's PTCT Position: Q2 2026 in Review

Versant Capital Management held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 28 shares worth $2.28K. The position accounts for ﹤0.01% of the portfolio, ranked #2546.

Versant Capital Management first reported a position in PTCT in Q2 2021 and has held it in 7 quarters since. 44 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Versant Capital Management held 28 shares of PTC Therapeutics worth $2.28K as of Q2 2026.
Versant Capital Management left its PTC Therapeutics share count unchanged in Q2 2026.
PTC Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2546 holding.
Versant Capital Management first reported a position in PTC Therapeutics in Q2 2021 and has held it in 7 quarters since.
44 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.